SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's has become a focal point for retail traders who are attempting to force a short squeeze, driven by high trading volume and active discussions on social media platforms about saving the brand. Community members are debating the company's valuation and potential upside, with many expressing bullish sentiment based on the stock's dividend and the hope for a dramatic price surge.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as market participants brace for earnings that are widely viewed as a make-or-break catalyst for the broader semiconductor and AI sector. The community is deeply divided, with discussions centered on whether recent volatility reflects a healthy shakeout before a post-earnings rally or a structural correction due to sky-high expectations and shifting demand cycles.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors digest the company's strategic move to acquire infrastructure startup Modular, a deal seen as a play to bridge the software gap and challenge Nvidia's software dominance in the AI data center market. The community remains divided, with some investors focusing on long-term AI potential and upcoming catalyst events, while others express frustration over recent stock volatility and the perceived lack of momentum despite these aggressive growth initiatives.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as investors react to the company's initiation of a Phase 1 clinical trial for VK3019, a novel obesity drug, while social media chatter intensifies around potential M&A activity and the stock's significant short interest. Community sentiment is driven by speculation regarding near-term partnerships or a buyout, with many long-term holders pointing to the upcoming Q3 maintenance study data as a critical catalyst to unlock value against competitors.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened investor scrutiny following the loss of several high-profile AI research leaders to key competitors, sparking concerns about the company's long-term talent retention and innovation momentum. While the community is actively debating the potential impact on Google's AI moat and the sustainability of massive infrastructure capital expenditures, many long-term bulls remain focused on the company's resilient core business, cloud growth, and strategic integration of Gemini across its ecosystem.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae is trending as retail investors and institutional players debate the timing of a potential IPO and the end of government conservatorship, fueled by recent commentary suggesting a significant valuation for the firm. While some participants are aggressively accumulating shares in anticipation of a massive catalysts, others express deep frustration and skepticism regarding the timeline and the influence of political rhetoric on price action.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and significant selling pressure as investors react to its heavy leverage on Bitcoin and ongoing concerns regarding its corporate debt structure. The community remains deeply polarized, with some traders betting on an oversold bounce or long-term upside, while others argue the stock is a precarious proxy for crypto that faces potential liquidation risks.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is facing heavy selling pressure as investors grapple with shifting interest rate expectations and a strengthening U.S. dollar, leading many in the community to weigh in on whether current levels represent a capitulation bottom or the start of a deeper cyclical correction. While some are doubling down on long-term physical accumulation citing supply deficits and industrial demand, others are expressing frustration over the lack of momentum and are actively debating the viability of holding silver against traditional growth equities.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor volatility and community debate as the stock faces heavy downward pressure despite a steady flow of positive catalysts, including recent collaboration news with Lockheed Martin and drone-sector defense contracts. Community discussion is sharply divided between retail bulls who are leveraging dips to accumulate shares ahead of potential index inclusion and bears pointing to persistent dilution, technical weakness, and algorithmic selling.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors digest a high-profile exit of key AI talent to Anthropic alongside a broader market rotation out of mega-cap tech. Despite these sentiment-driven pullbacks, the community remains intensely focused on the company's massive AI infrastructure spend and the strategic index inclusion into the Dow Jones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABEO $6.39 bid. DAC (dollar average cost) $4.21 (5.30.24). EXIT $9.00). 
UPDATE:  Announces the Company  resubmitted its Biologics License Application to the U.S. FDA for prademagene zamikeracel, its investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa note:  Abeona expects the FDA to set a new Prescription Drug User Fee Act target action date for pz-cel. The review period for a resubmitted BLA is either two or six months from the resubmission date depending on the FDA&#39;s classification of a resubmission as Class 1 or Class 2, respectively.  
^^ The FDA&#39;s decision on acceptance of a BLA resubmission is typically made within 14 calendar days following the resubmission.

Ignacio Alcacer Mackinlay

JimiJo Jeeter

Tim Clancy

Sally

StockTwits Web

Abeona Therapeutics Inc

 $6.39 bid. DAC (dollar average cost) $4.21 (5.30.24). EXIT $9.00). 
UPDATE:  Announces the Company  resubmitted its Biologics License Application to the U.S. FDA for prademagene zamikeracel, its investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa note:  Abeona expects the FDA to set a new Prescription Drug User Fee Act target action date for pz-cel. The review period for a resubmitted BLA is either two or six months from the resubmission date depending on the FDA's classification of a resubmission as Class 1 or Class 2, respectively.  
^^ The FDA's decision on acceptance of a BLA resubmission is typically made within 14 calendar days following the resubmission.